DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo- and active-controlled study of a new
experimental drug called darusentan. Darusentan is not currently approved by the United
States Food and Drug Administration (FDA), which means that a doctor cannot prescribe this
drug. The purpose of this study is to determine if darusentan is effective in reducing
systolic and diastolic hypertension despite treatment with full doses of three or more
antihypertensive drugs, including a diuretic. Subjects will be randomized to darusentan
(optimized dose), an active comparator, or placebo, administered orally. The treatment period
for this trial is 14 weeks.